Matt Shoemaker to undergo MRI on sprained left knee

Matt Shoemaker
AP Images
1 Comment

Blue Jays starter Matt Shoemaker has been diagnosed with a left knee sprain following his early departure from Saturday’s game. He’s scheduled to undergo an MRI on Sunday, after which the club will be able to determine the extent of his injury and draw up a more definite timeline for his return to the mound.

The right-hander held the A’s scoreless through three innings of three-hit, one-strikeout ball on Saturday. In the bottom of the third, with two outs and Matt Chapman on first, Shoemaker helped complete an inning-ending putout after Chapman tried to steal second. He tagged Chapman between first and second base, but appeared to twist his leg in the process and immediately started limping away.

Shoemaker was helped off the field after the play and was swiftly replaced by righty Sam Gaviglio in the bottom of the fourth. This is the first serious injury the 32-year-old has sustained since he underwent forearm surgery and missed nearly all of his 2018 campaign with the Angels. While he’s not expected to be sidelined for quite as long this time around, it’s still a concerning setback for the Blue Jays’ no. 2 starter, who currently boasts a sterling 1.57 ERA, 2.8 BB/9, and 7.5 SO/9 through his first 28 2/3 innings of 2019.

The Blue Jays will undoubtedly feel the lack of Shoemaker’s presence over the next few days, but they managed deliver a blowout win on Saturday even without his help. Behind six innings of one-run ball from Gaviglio and Elvis Luciano, the offense mustered up 10 runs — the most they’ve collected in a single game all season — and kept the A’s hardest hits at bay with impressive catches from Billy McKinney and Freddy Galvis.

MLB, union resume blood testing after pandemic, lockout

Scott Taetsch-USA TODAY Sports
0 Comments

NEW YORK – In the first acknowledgment that MLB and the players’ association resumed blood testing for human growth hormone, the organizations said none of the 1,027 samples taken during the 2022 season tested positive.

HGH testing stopped in 2021 because of the COVID-19 pandemic. Testing also was halted during the 99-day lockout that ended in mid-March, and there were supply chain issues due to COVID-19 and additional caution in testing due to coronavirus protocols.

The annual public report is issued by Thomas M. Martin, independent program administrator of MLB’s joint drug prevention and treatment program. In an announcement accompanying Thursday’s report, MLB and the union said test processing is moving form the INRS Laboratory in Quebec, Canada, to the UCLA Laboratory in California.

MLB tests for HGH using dried blood spot testing, which was a change that was agreed to during bargaining last winter. There were far fewer samples taken in 2022 compared to 2019, when there were 2,287 samples were collected – none positive.

Beyond HGH testing, 9,011 urine samples were collected in the year ending with the 2022 World Series, up from 8,436 in the previous year but down from 9,332 in 2019. And therapeutic use exemptions for attention deficit hyperactivity disorder dropped for the ninth straight year, with just 72 exemptions in 2022.

Overall, the league issued six suspensions in 2022 for performance-enhancing substances: three for Boldenone (outfielder/first baseman Danny Santana, pitcher Richard Rodriguez and infielder Jose Rondon, all free agents, for 80 games apiece); one each for Clomiphene (Milwaukee catcher Pedro Severino for 80 games), Clostebol (San Diego shortstop Fernando Tatis Jr. for 80 games) and Stanozolol (Milwaukee pitcher J.C. Mejia for 80 games).

There was an additional positive test for the banned stimulant Clobenzorex. A first positive test for a banned stimulant results in follow-up testing with no suspension.